First Patient Dosed in Phase 1 Trial of P-BCMA-101 CAR T-Cell Therapy for Multiple Myeloma – Myeloma Research News
Myeloma Research News |
First Patient Dosed in Phase 1 Trial of P-BCMA-101 CAR T-Cell Therapy for Multiple Myeloma
Myeloma Research News The first patient has been dosed in a Phase 1 trial of P-BCMA-101, a new, more powerful type of CAR T-cell therapy to fight multiple myeloma, the therapy's developer, Poseida Therapeutics, announced. The trial (NCT03288493), which will test the safety … |
